AI Regulation: EU Network Announces Four-Year Action Plan

 
• By Eliza Slawther
  
Generate a summary of this article
Listen to this article
Beta

Multiple guidance documents, a regulatory sandbox, and the creation of an “observatory” to monitor the emergence of new technologies are some of the actions being considered by the European medicines regulatory network under its AI regulatory system workplan.

Workplan
• Source: Shutterstock

The European medicines regulatory network – the group comprising the European Medicines Agency, the European Commission, and member states’ national competent authorities – has revealed a multi-annual workplan that will run until 2028 and, it hopes, lead to the creation of a regulatory system equipped to deal with the challenges and risks of artificial intelligence.

“There is a vision from the European medicines regulatory network,” said Luis Pinheiro, a senior epidemiology expert at the EMA,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from AI

Artificial Intelligence: CDER’s New Council Takes Charge Of Oversight, Coordination

 
• By Sue Sutter

The Artificial Intelligence Council takes over the work that three different entities in the US FDA’s drugs center had been performing. The new, centralized entity will develop and promote consistency of AI-related activities and advance innovative uses.

Use AI In Health Technology Assessments Only When Valuable, England’s NICE Tells Pharma Firms

 
• By Eliza Slawther

Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.

$14m Handout Anyone? Shanghai Offers Raft Of New Biopharma Incentives

 
• By Brian Yang

Shanghai issues a new set of policies and financial incentives designed to support and speed up regulatory and commercial activities in the biopharma sector, in a comprehensive stimulus package for companies based in the major Chinese city.

Parexel Execs On Regulatory Harmonization, AI Impact, RWE Challenges

 
• By Vibha Ravi

From the US FDA’s ISTAND Program to EU’s Melloddy Initiative, and from the global challenges of real-world data to the opportunities in India, Parexel’s EVP for Clinical Data and Digital Services, chief strategy officer and India head speak on a range of topics in this interview with the Pink Sheet.

More from Advanced Technologies

CAR-T Therapies: Rethinking Of Postmarketing Requirements And REMS Urged

 
• By Sue Sutter

Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.

test

 
• By Sabbah and Saba Afreen

test

Gene Therapies: CoGenT Pilot Could Help With Regulatory Convergence Earlier In Development TEST

 
• By Sue Sutter

Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.